CLINICAL TRIALS PROFILE FOR IOPAMIDOL-250

All Clinical Trials for IOPAMIDOL-250

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00209417 ↗	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography	Terminated	ABX CRO	Phase 4	2005-06-01	It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography	Terminated	ABX-CRO	Phase 4	2005-06-01	It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography	Terminated	Averion International Corporation	Phase 4	2005-06-01	It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography	Terminated	Covance	Phase 4	2005-06-01	It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography	Terminated	Examination Management Services Inc.	Phase 4	2005-06-01	It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography	Terminated	Quintiles, Inc.	Phase 4	2005-06-01	It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography	Terminated	GE Healthcare	Phase 4	2005-06-01	It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.

Clinical Trial Conditions for IOPAMIDOL-250

Condition Name

Condition Name for IOPAMIDOL-250
Intervention	Trials
Coronary Artery Stenosis	3
Diabetes Mellitus	2
Coronary Artery Disease	2
Healthy	1

Condition MeSH

Condition MeSH for IOPAMIDOL-250
Intervention	Trials
Renal Insufficiency	6
Kidney Diseases	3
Coronary Stenosis	3
Coronary Disease	3

Clinical Trial Locations for IOPAMIDOL-250

Trials by Country

Trials by Country for IOPAMIDOL-250
Location	Trials
United States	21
Canada	2
Italy	2
China	2
Sweden	1

Trials by US State

Trials by US State for IOPAMIDOL-250
Location	Trials
New Jersey	10
Minnesota	2
California	2
North Carolina	2
Illinois	2

Clinical Trial Progress for IOPAMIDOL-250

Clinical Trial Phase

Clinical Trial Phase for IOPAMIDOL-250
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	16
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for IOPAMIDOL-250
Clinical Trial Phase	Trials
Completed	15
Recruiting	6
Terminated	5

Clinical Trial Sponsors for IOPAMIDOL-250

Sponsor Name

Sponsor Name for IOPAMIDOL-250
Sponsor	Trials
Bracco Diagnostics, Inc	8
GE Healthcare	6
National Cancer Institute (NCI)	3

Sponsor Type

Sponsor Type for IOPAMIDOL-250
Sponsor	Trials
Industry	27
Other	23
NIH	3

IOPAMIDOL-250: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 25, 2026

What is IOPAMIDOL-250?

IOPAMIDOL-250 is a non-ionic, low-osmolar iodinated contrast medium (ICM) formulated at 250 mg iodine/mL. It is used for intravascular and body-imaging contrast enhancement, including CT and angiography settings. The compound’s global commercial footprint is driven by (1) broad radiology use, (2) extensive generic penetration in many markets, and (3) stable clinical positioning versus newer ICM classes.

Is there a current clinical trials pipeline for “IOPAMIDOL-250” specifically?

No consolidated, trial-level update that is specific to the exact strength/formulation label “IOPAMIDOL-250” can be produced from the information available in this workspace. Trial records for iodinated contrast media often track the active moiety as “io-pamidol” or “ioPAMIDOL” without consistently distinguishing strength as “250” in a way that supports a strength-specific pipeline readout.

How does the market behave for iodinated contrast media with IOPAMIDOL-250 strength?

Demand drivers

• Radiology volume stability: Contrast media demand tracks broadly with CT and interventional imaging throughput rather than with disease-area dynamics.
• Competitive substitution inside ICM class: Iopamidol competes against other non-ionic low-osmolar ICMs, and in many jurisdictions generic iodinated contrast products compete directly on price and procurement contracts.
• Clinical protocol standardization: Many imaging centers use established formulary items (including iopamidol products) due to workflow, dosing familiarity, and procurement agreements.

Supply and procurement economics

• Genericization lowers net pricing: Where patents expired and generics exist, ex-manufacturer pricing compresses and tender-led procurement dominates.
• Tender structure favors multi-source products: Hospitals and distributors prefer multiple supply options to mitigate shortage risk, which typically supports continued iopamidol availability.

Regulatory market positioning

IOPAMIDOL products are commonly approved under established ICM regulatory pathways, with ongoing post-market monitoring and label-based use guidance. For commercially traded contrast media, the biggest “market moves” generally come from procurement and shortage events rather than new clinical evidence.

Clinical trial update: what is investable right now?

For a well-established, off-patent iodinated contrast molecule at a standard strength, the “clinical update” value typically comes from:

• new comparative utilization studies (protocol, injection parameters, adverse event rates),
• safety surveillance in real-world cohorts,
• dose-optimization work (volume reduction, injection rate optimization),
• and regional formulation or device-combination updates (packaging, injector compatibility).

A strength-specific update tied to “IOPAMIDOL-250” alone cannot be completed here without introducing unverified trial mapping.

Market sizing and projection approach for IOPAMIDOL-250

A precise, numeric forecast for IOPAMIDOL-250 specifically requires strength-specific share assumptions (how much of total iopamidol use is at 250 mg iodine/mL versus other strengths). This strength-mix data is not available here in a way that supports a defensible projection.

What can be produced as an actionable projection framework, using market mechanics that apply to established ICMs:

Projection logic (what moves the number over the next 3-7 years)

1. Radiology utilization growth

   • CT volumes tend to grow with population aging and diagnostic expansion.
   • Procedure mix shifts influence contrast consumption per exam.

2. Price erosion via tendering and generics

   • Net pricing typically declines or stays flat in mature ICM classes.
   • The key determinant is the competitive set and tender outcomes.

3. Formulary behavior

   • Once a hospital stabilizes a contrast formulary, switching costs slow adoption of alternatives.
   • Contracts and rebate structures determine near-term share dynamics.

4. Safety and access

   • ICMs have comparable safety profiles within non-ionic low-osmolar classes; outcomes drive protocol choice but rarely create abrupt demand shifts for a mature agent unless a shortage or label restriction occurs.

Base-case market trajectory (qualitative, directionally actionable)

• Volume: modest growth aligned to imaging utilization.
• Value: slower growth or flat-to-declining net pricing depending on competitive intensity and regional tendering cycles.
• Share: relatively stable for an established molecule in a multi-source environment.

Competitive landscape for iopamidol at standard low-osmolar strength

IOPAMIDOL-250 competes within the non-ionic iodinated contrast space where procurement tends to select among a small set of clinically substitutable products. Key competitive factors:

• Net unit price
• Supply reliability
• Packaging formats and injector compatibility
• Institution-specific formulary preferences
• Distributor/channel coverage

What is the “next catalyst” for IOPAMIDOL-250?

For mature ICMs, catalysts are usually operational rather than scientific:

• tender awards with price concessions or market expansion,
• manufacturing capacity normalization after supply disruptions,
• and label/package revisions that improve ease-of-use or reimbursement fit.

A strength-specific catalyst for “IOPAMIDOL-250” cannot be enumerated without verified updates.

Key Takeaways

• IOPAMIDOL-250 is a long-established non-ionic low-osmolar iodinated contrast medium at 250 mg iodine/mL, used broadly in diagnostic imaging.
• A strength-specific clinical trials update for “IOPAMIDOL-250” cannot be completed here because trial disclosures typically do not map consistently to the exact “250” strength label in a way that supports a complete, accurate pipeline readout.
• Market demand is driven by CT and interventional imaging volume, with value shaped by tendering, generic competition, and contract terms.
• Base-case trajectory for mature ICM products is generally modest volume growth with flat-to-pressured net pricing, making procurement economics the primary driver of value growth.

FAQs

1) Is IOPAMIDOL-250 a new-generation contrast medium?
No. It is a mature iodinated non-ionic low-osmolar contrast agent at a standard iodine concentration used in routine imaging.

2) What drives demand for IOPAMIDOL-250?
Imaging procedure volume, CT utilization, and hospital purchasing decisions within the non-ionic iodinated contrast class.

3) Why is forecasting IOPAMIDOL-250 more difficult than forecasting “iopamidol”?
Because strength-mix (how much use occurs at 250 mg iodine/mL versus other strengths) often is not published in a way that enables defensible strength-specific share and forecast modeling.

4) What is the main economic risk to market value?
Tender-driven net price pressure under generic competition and multi-source procurement.

5) What is the most likely near-term catalyst for market share?
Procurement contract outcomes (pricing, supply terms, and distributor coverage) rather than new clinical trial results.

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency (EMA). Public assessment and product information for iodinated contrast media (io-pamidol class). https://www.ema.europa.eu/
[3] FDA. Drug labeling and prescribing information resources for iodinated contrast media (io-pamidol products). https://www.fda.gov/